Latest Insider Positions


SNYDERMAN RALPH is listed as an insider in the following companies: LQDA / Liquidia Technologies Inc ARGS / Argos Therapeutics, Inc. CDNA / CareDx, Inc. IRTC / iRhythm Technologies, Inc. PGND / Press Ganey Holdings, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
CDNA / CareDx Director 70,485
LQDA / Liquidia Technologies Director 49,724
IRTC / iRhythm Technologies Director 3,142
ARGS / Argos Therapeutics Director 573
PGND / Press Ganey Holdings Director 0

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-10-01 CDNA / CareDx A 489 70,485 0.70
LQDA / Liquidia Technologies 49,724
LQDA / Liquidia Technologies 49,724
LQDA / Liquidia Technologies 49,724
2018-06-29 CDNA / CareDx A 1,197 69,996 1.74
2018-06-20 CDNA / CareDx A 5,000 68,799 7.84
2018-05-23 IRTC / iRhythm Technologies A 1,193 3,142 61.21
2018-04-02 CDNA / CareDx A 2,221 63,799 3.61
2018-01-02 CDNA / CareDx A 1,924 61,578 3.23
2017-10-02 CDNA / CareDx A 5,713 59,654 10.59
2017-07-17 IRTC / iRhythm Technologies A 1,949 1,949
2017-07-13 CDNA / CareDx A 5,000 53,941 10.22
2017-07-03 CDNA / CareDx A 7,534 48,941 18.19
2017-04-01 CDNA / CareDx A 5,384 41,407 14.95
2017-01-01 CDNA / CareDx A 3,463 36,023 10.64
2016-12-31 ARGS / Argos Therapeutics A 573 573
2016-10-21 PGND / Press Ganey Holdings D -28,770 0 -100.00 40.50 -1,165,185
2016-10-01 CDNA / CareDx A 2,614 32,560 8.73
2016-07-15 CDNA / CareDx A 5,000 29,946 20.04
2016-07-01 CDNA / CareDx A 1,653 24,946 7.10
2016-06-21 PGND / Press Ganey Holdings A 3,402 28,770 13.41
2016-04-01 CDNA / CareDx A 2,247 23,293 10.68
2016-01-01 CDNA / CareDx A 2,112 21,046 11.15
2015-10-01 CDNA / CareDx A 1,739 18,934 10.11
2015-07-01 CDNA / CareDx A 2,117 17,195 14.04
2015-05-21 PGND / Press Ganey Holdings A 5,000 25,368 24.55
2015-04-22 CDNA / CareDx M 11,678 15,078 343.47 2.329 27,198
2015-04-01 CDNA / CareDx A 1,440 3,400 73.47
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of SNYDERMAN RALPH include the following: 1118 Ltd, A.M. Pappas Life Science Ventures IV LP, AL WEALTH PARTNERS PTE. LTD., ALLEN LEE F MD PhD, ALWP CAPITAL SPC LTD, AMP&A Management IV, LLC, Abbey Jeffrey D, Abernethy Amy, Adair Jason, Albury Timothy, Alexandria Venture Investments, LLC, Amereus Group PTE LTD, Anderson Devin J, Aynechi Tiba, BARRETT M JAMES, BARRIS PETER J, BASKETT FOREST, BYERS BROOK H, Bairey Merz Cathleen Noel, Bathurst Enterprises Ltd, Bell Michael Brian, Bickerstaff George, Bill & Melinda Gates Foundation, Birner Hubert, Bloch Stephen M, Bodaken Bruce G., Canaan Partners VIII LLC, Canaan VIII LP, Carey Robert, Chambon Philippe O., Cmielewski Patricia, Cohen Fred E, Constanti Charles, Costello David J., Crowe Jeffrey, DRISCOLL JOHN PATRICK, DeFonzo Joshua, DeSimone Joseph, DeSimone Suzanne, Delagardelle Jeani, Eagle Holding Co I, Eagle Holding Co II, LLC, FEIGH BREHT T, ForArgos B.V., Fowler Neal Franklin, GAGNON NEIL, GLAXOSMITHKLINE PLC, GORDON KEVIN K, Garden East Ltd, Garrett Matthew C., Glaser John P, Glidden Shawn, Goldberg Michael, Greskoviak Joseph P, HAGSTROM WILLIAM A, HAQUE PROMOD, HUNT RONALD, Hallgren Matthew, Harrelson Lori R., Howard Matthew D., Jaguar Holding Co I, LLC, Jaguar Holding Co II, Jain Mudit K., KERINS PATRICK J, Karlsson Anders, Karti Karim, Katz Richard D, King Kevin M, King Sasha, Kirsch Arthur S, Krol Igor, LEERINK REVELATION HEALTHCARE FUND I, L.P., LUDLUM KEN, Lamarre Jean, Lathi Vijay K, Leerink Revelation Healthcare Fund I GP, L.P., Lippe Robert A, MIESOWICZ FREDERICK, MILLER DOUGLAS S, MORRISON RICHARD G, Maag Peter, Mario Family Credit LLC Series D, Mario Jeremy, Mathers Edward T, Maynor Benjamin, Medical Mutual Holdings, Inc., Melmotte LLC, Meyer Matthew J., Midroc Invest AB, Morningside Venture Investments Ltd, Mtibelishvily Irackly, NEA 12 GP, LLC, NEA Partners 12, Limited Partnership, Nelles Mitchell J, New Enterprise Associates 12, Limited Partnership, New Leaf Venture Associates II, L.P., New Leaf Venture Management II, L.L.C., New Leaf Ventures II, L.P., Nicolette Charles A., Norwalk Leslie V, Norwest Venture Partners XI, LP, Norwest Venture Partners XII, LP, Novo A/S, OCONNELL DANIEL S, PAPPAS ARTHUR M, PAPPAS CAPITAL, LLC, PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, PV IV CEO Fund, L.P., Petrov Andrei Vladimirovich, Pharmstandard International S.A., Plessinger Douglas C., Public Joint Stock Co Pharmstandard, ROTH GREG, RUBASH MARK J, RUDNICK SETH, Ratcliffe Liam, Riskind Patricia L., Roscigno Robert F, Ryan Patrick T, SANDELL SCOTT D, SINGH RAMAN, SYNERGY LIFE SCIENCE PARTNERS L P, Scott Raymond W., Sninsky John Joseph, Sovereign's Capital II, LP, Stack Richard S., Starling William N JR, Sung Derrick, Suvarna Suda, Synergy Venture Partners, LLC, TALWALKAR ABHIJIT Y, Thomas Jeri, Underdown Brian J., University of North Carolina at Chapel Hill Foundation, Inc., VESTAR ASSOCIATES V, L.P., VESTAR MANAGERS V LTD., VOROBYEV MAXIM YURYEVICH, Van Holle Philippe Marie Marcel Joseph, Vestar Capital Partners V A L P, Vestar Capital Partners V L P, Vestar Capital Partners V-B LP, Vestar Co-Invest V, L.P., Vestar Executives V LP, Vestar Investors V, L.P., Vestar/PGA Investors, LLC, Vinogradov Alexey Alexandrovich, Vort David A, Wakefield Group III, LLC, Wakefield Group IV, LLC, Whitson Todd, Wildcat Acquisition Holdings (UK) Ltd, Winterbottom Joan, Xeraya LT Ltd, Yee James P, Zahir Fares, Zane Ellen M, de Clercq Casper L., van Deventer Sander, . Peers are determined by cross-linking the filings of SNYDERMAN RALPH with insider filings of others at the same companies.

Related News Stories

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-09-18 zacks
Designed to provide broad exposure to the Small Cap Blend segment of the US equity market, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund launched on 07/19/2012. (9-0)

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-24 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market. (6-0)

Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?

2018-08-13 zacks
Teladoc Health, Inc. (TDOC - Free Report) stock gained traction from a strong second-quarter 2018 earnings release as well as a solid guidance. The stock hit a 52 week-high of $71.9 on Aug 10. (5-0)

CareDx, Inc. (CDNA) CEO Peter Maag on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Greetings, and welcome to the CareDx Second Quarter 2018 Earnings Conference Call. At this time all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (4-0)

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks
CareDx (CDNA - Free Report) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. (4-0)